BRPI0509745A - compostos de difenil ox-indol-2-ona e seu uso no tratamento de cáncer - Google Patents
compostos de difenil ox-indol-2-ona e seu uso no tratamento de cáncerInfo
- Publication number
- BRPI0509745A BRPI0509745A BRPI0509745-2A BRPI0509745A BRPI0509745A BR PI0509745 A BRPI0509745 A BR PI0509745A BR PI0509745 A BRPI0509745 A BR PI0509745A BR PI0509745 A BRPI0509745 A BR PI0509745A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- indol
- cancer
- diphenyl
- dihydro
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 201000011510 cancer Diseases 0.000 title abstract 3
- 235000010290 biphenyl Nutrition 0.000 title 1
- 239000004305 biphenyl Substances 0.000 title 1
- 125000006267 biphenyl group Chemical group 0.000 title 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 title 1
- 206010039491 Sarcoma Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- KLAWNELUVVBFGB-UHFFFAOYSA-N 3,3-diphenyl-1h-indol-2-one Chemical class O=C1NC2=CC=CC=C2C1(C=1C=CC=CC=1)C1=CC=CC=C1 KLAWNELUVVBFGB-UHFFFAOYSA-N 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000008839 Kidney Neoplasms Diseases 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 206010038389 Renal cancer Diseases 0.000 abstract 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 abstract 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 abstract 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 208000010749 gastric carcinoma Diseases 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 201000010982 kidney cancer Diseases 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 238000001243 protein synthesis Methods 0.000 abstract 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 abstract 1
- 206010041823 squamous cell carcinoma Diseases 0.000 abstract 1
- 201000000498 stomach carcinoma Diseases 0.000 abstract 1
- 230000014616 translation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200400576 | 2004-04-08 | ||
| DKPA200400693 | 2004-05-01 | ||
| DKPA200401153 | 2004-07-27 | ||
| DKPA200401216 | 2004-08-11 | ||
| PCT/DK2005/000244 WO2005097107A2 (en) | 2004-04-08 | 2005-04-08 | Diphenyl - indol-2-on compounds and their use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0509745A true BRPI0509745A (pt) | 2007-09-25 |
Family
ID=34965522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0509745-2A BRPI0509745A (pt) | 2004-04-08 | 2005-04-08 | compostos de difenil ox-indol-2-ona e seu uso no tratamento de cáncer |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20070299102A1 (enExample) |
| EP (1) | EP1734951A2 (enExample) |
| JP (1) | JP2007532496A (enExample) |
| KR (1) | KR20060130781A (enExample) |
| CN (1) | CN1953747A (enExample) |
| AU (1) | AU2005230232A1 (enExample) |
| BR (1) | BRPI0509745A (enExample) |
| CA (1) | CA2562399A1 (enExample) |
| CR (1) | CR8673A (enExample) |
| EA (1) | EA013209B1 (enExample) |
| EC (1) | ECSP066913A (enExample) |
| IL (1) | IL178012A0 (enExample) |
| NO (1) | NO20065034L (enExample) |
| NZ (1) | NZ550222A (enExample) |
| WO (1) | WO2005097107A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2555812A1 (en) * | 2004-02-13 | 2005-09-01 | President And Fellows Of Harvard College | 3-3-di-substituted-oxindoles as inhibitors of translation initiation |
| MY144968A (en) * | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| AR053710A1 (es) | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
| AR053713A1 (es) * | 2005-04-20 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos heterociclicos y sus usos como agentes terapeuticos |
| EP1946120A2 (en) * | 2005-10-18 | 2008-07-23 | George Mason Intellectual Properties, Inc. | Mtor pathway theranostic |
| MX2009003875A (es) * | 2006-10-12 | 2009-04-22 | Xenon Pharmaceuticals Inc | Derivados y compuestos relacionados de espiro(furo[3,2-c]piridina- 3,3'-indol)-2' (1'h)ona para el tratamiento de enfermedades mediadas por los canales de sodio, tal como dolor. |
| JP2010522690A (ja) * | 2006-10-12 | 2010-07-08 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 三環式スピロオキシインドール誘導体および治療薬としてのその使用 |
| MX2009003876A (es) | 2006-10-12 | 2009-05-11 | Xenon Pharmaceuticals Inc | Uso de compuestos de espiro-oxindol como agentes terapeuticos. |
| JP2010512355A (ja) * | 2006-12-11 | 2010-04-22 | トポターゲット・アクティーゼルスカブ | 癌の処置のためのジフェニルオキシ−インドール−２−オン化合物のプロドラッグ |
| JP2010525024A (ja) * | 2007-04-24 | 2010-07-22 | トポターゲット・アクティーゼルスカブ | 置換３−（４−ヒドロキシフェニル）−インドリン−２−オン化合物 |
| GEP20125664B (en) | 2008-02-26 | 2012-10-10 | Takeda Pharmaceuticals Co | Condensed heterocyclic derivatives and application thereof |
| US20100048913A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
| AU2009225434B2 (en) | 2008-03-21 | 2014-05-22 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
| PT2350090E (pt) | 2008-10-17 | 2015-11-13 | Xenon Pharmaceuticals Inc | Composto espiro-oxindol e suas utilizações como agentes terapêuticos |
| WO2010045197A1 (en) * | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals, Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| US8110578B2 (en) * | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| EP2393827B1 (en) | 2009-02-05 | 2015-10-07 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
| WO2010109008A1 (en) | 2009-03-26 | 2010-09-30 | Topotarget A/S | Prodrugs of substituted 3-(4-hydroxyphenyl)-indolin-2-ones |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| PE20121350A1 (es) | 2009-10-14 | 2012-10-20 | Xenon Pharmaceuticals Inc | Metodos sinteticos para compuestos espiro-oxoindol |
| US20110086899A1 (en) * | 2009-10-14 | 2011-04-14 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
| KR20120095402A (ko) | 2009-10-23 | 2012-08-28 | 파나셀라 랩스, 아이엔씨. | 안드로겐 수용체 양성 암의 치료 방법 |
| PE20121699A1 (es) | 2010-02-26 | 2012-12-22 | Xenon Pharmaceuticals Inc | Composiciones farmaceuticas del compuesto espiro-oxindol para administracion topica |
| AU2014207272A1 (en) * | 2013-01-18 | 2015-07-30 | Neal D. Andruska | Estrogen receptor inhibitors |
| SG11201507093WA (en) | 2013-03-14 | 2015-10-29 | Univ Maryland Baltimore Office Of Technology Transfer | Androgen receptor down-regulating agents and uses thereof |
| SG11201600525XA (en) | 2013-08-12 | 2016-02-26 | Tokai Pharmaceuticals Inc | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
| EP3094314B1 (en) | 2014-01-16 | 2021-06-23 | MUSC Foundation For Research Development | Targeted nanocarriers for the administration of immunosuppressive agents |
| TW201636017A (zh) | 2015-02-05 | 2016-10-16 | 梯瓦製藥國際有限責任公司 | 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法 |
| EP3749302B1 (en) * | 2018-02-08 | 2024-10-23 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Oxyphenisatin acetate, oxyphenisatin and bisacodyl for treating triple-negative breast cancer |
| EA202190146A1 (ru) * | 2018-07-03 | 2021-04-27 | Те Борд Оф Трастиз Оф Те Юниверсити Оф Иллинойс | Активаторы реакции на несложенные белки |
| EP3912625A1 (en) * | 2020-05-20 | 2021-11-24 | Kaerus Bioscience Limited | Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders |
| CN114213396B (zh) * | 2022-01-27 | 2023-03-24 | 深圳市乐土生物医药有限公司 | 一种吲哚-2-酮类化合物及其制备方法与用途 |
| CN119019312B (zh) * | 2024-10-24 | 2025-01-28 | 苏州宜联生物医药有限公司 | 一种吲哚-2-酮衍生物、其抗体药物偶联物及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2258505A1 (de) * | 1971-12-02 | 1973-06-07 | Ciba Geigy Ag | Oxindoldiamine und verfahren zu ihrer herstellung |
| ES426436A1 (es) * | 1974-05-18 | 1976-07-01 | Andreu Sa Dr | Procedimiento para la obtencion de derivados de la 3,3-bis (4-hidroxifenil)-2-indolinona. |
| JPS5590943A (en) * | 1978-12-28 | 1980-07-10 | Fuji Photo Film Co Ltd | Photosensitive material and image forming method applicable thereto |
| DE3510730A1 (de) * | 1985-03-08 | 1986-09-11 | Möve-Werk GmbH & Co KG, 7410 Reutlingen | Verfahren zur herstellung eines baumwollgewebes |
| US6800658B2 (en) * | 1997-11-20 | 2004-10-05 | Children's Medical Center Corporation | Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment of prevention of diseases characterized by abnormal cell proliferation |
| IL136227A (en) * | 1997-11-20 | 2005-09-25 | Harvard College | Pharmaceutical compositions comprising substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment or prevention of diseases characterized by abnornal cell proliferation and some such novel compounds |
| US6391907B1 (en) * | 1999-05-04 | 2002-05-21 | American Home Products Corporation | Indoline derivatives |
| WO2003078394A1 (en) * | 2002-03-15 | 2003-09-25 | Eli Lilly And Company | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators |
| CA2555812A1 (en) * | 2004-02-13 | 2005-09-01 | President And Fellows Of Harvard College | 3-3-di-substituted-oxindoles as inhibitors of translation initiation |
-
2005
- 2005-04-08 CA CA002562399A patent/CA2562399A1/en not_active Abandoned
- 2005-04-08 CN CNA2005800102502A patent/CN1953747A/zh active Pending
- 2005-04-08 AU AU2005230232A patent/AU2005230232A1/en not_active Abandoned
- 2005-04-08 NZ NZ550222A patent/NZ550222A/en unknown
- 2005-04-08 KR KR1020067023439A patent/KR20060130781A/ko not_active Ceased
- 2005-04-08 BR BRPI0509745-2A patent/BRPI0509745A/pt not_active IP Right Cessation
- 2005-04-08 US US10/599,121 patent/US20070299102A1/en not_active Abandoned
- 2005-04-08 EA EA200601879A patent/EA013209B1/ru not_active IP Right Cessation
- 2005-04-08 EP EP05715161A patent/EP1734951A2/en not_active Withdrawn
- 2005-04-08 WO PCT/DK2005/000244 patent/WO2005097107A2/en not_active Ceased
- 2005-04-08 JP JP2007506660A patent/JP2007532496A/ja active Pending
-
2006
- 2006-09-11 IL IL178012A patent/IL178012A0/en unknown
- 2006-10-05 CR CR8673A patent/CR8673A/es not_active Application Discontinuation
- 2006-10-10 EC EC2006006913A patent/ECSP066913A/es unknown
- 2006-11-02 NO NO20065034A patent/NO20065034L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005230232A1 (en) | 2005-10-20 |
| CA2562399A1 (en) | 2005-10-20 |
| WO2005097107A3 (en) | 2006-03-30 |
| WO2005097107A8 (en) | 2006-02-16 |
| JP2007532496A (ja) | 2007-11-15 |
| KR20060130781A (ko) | 2006-12-19 |
| ECSP066913A (es) | 2007-02-28 |
| NZ550222A (en) | 2010-09-30 |
| EA200601879A1 (ru) | 2007-04-27 |
| NO20065034L (no) | 2006-11-02 |
| CN1953747A (zh) | 2007-04-25 |
| EP1734951A2 (en) | 2006-12-27 |
| CR8673A (es) | 2007-07-19 |
| US20070299102A1 (en) | 2007-12-27 |
| WO2005097107A2 (en) | 2005-10-20 |
| EA013209B1 (ru) | 2010-04-30 |
| IL178012A0 (en) | 2006-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0509745A (pt) | compostos de difenil ox-indol-2-ona e seu uso no tratamento de cáncer | |
| RU2014108042A (ru) | Фармацевтическая композиция для лечения и профилактики злокачественной опухоли | |
| UA116188C2 (uk) | Інгібітори фосфатидилінозит-3-кінази і способи їх застосування | |
| RU2014108045A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
| RU2014108043A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
| RU2014108049A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
| PT1255537E (pt) | Inibidores da proteina farnesil transferase para tratar cancro da mama | |
| PL353750A1 (en) | Dosages for treatment with anti-erbb2 antibodies | |
| EA201290062A1 (ru) | Соединения, связывающие белки теплового шока, композиции и способы получения указанных соединений | |
| CY1118763T1 (el) | Αντισωμα αντι-ερηα2 | |
| IL178675A0 (en) | Monocyclic heterocycles as kinase inhibitors | |
| TR200003879T2 (tr) | İn vivo ışın tedavisine duyarlılaştırıcı özelliklere sahip farnesil protein transferaz inhibitörleri@ | |
| CY1107147T1 (el) | Παραγωγα ινδαζολης και φαρμακευτικες συνθεσεις για αναστολη των κινασων πρωτεϊνης και μεθοδοι για τη χρηση τους | |
| Karakosta et al. | Genetic models of human cancer as a multistep process. Paradigm models of colorectal cancer, breast cancer, and chronic myelogenous and acute lymphoblastic leukaemia. | |
| DK1556058T3 (da) | Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi | |
| MX2022000310A (es) | Inhibidores de proteina bcl-2. | |
| Hacker et al. | The DEK oncoprotein functions in ovarian cancer growth and survival | |
| ATE238981T1 (de) | Antitumorwirkstoffe | |
| WO2005094348A3 (en) | Anti-lfl2 antibodies for the diagnosis, prognosis and treatment of cancer | |
| BRPI0408257A (pt) | uso de derivados de isoquinolina para tratar cáncer e doenças relacionadas com quinase map | |
| UA85087C2 (en) | Monocyclic heterocycles as kinase inhibitors | |
| Liu et al. | Bmi-1-targeting suppresses osteosarcoma aggressiveness through the NF-κB signaling pathway | |
| GB0012526D0 (en) | Triterpenoid derivatives | |
| BR0215689A (pt) | Composição farmacêutica compreendendo arsênico para o tratamento de malignidade | |
| NZ595490A (en) | Derivatives of kahalalide F for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |